Background/Introduction: Acute kidney injury (AKI) is common in acute hospital admission and associated with worse patient outcomes. Aim: To measure incidence, care quality and outcome of AKI in admitted hospital care. Design: Forty-six of 168 acute NHS healthcare trusts in UK caring for 2 million acute hospital admissions per annum collected information on adults identified with AKI stage 3 (3-fold rise in serum creatinine or creatinine >354 mmol/l) through routine biochemical testing over a 5-month period in 2012. Methods: Information was collected on patient and care characteristics. Primary outcomes were survival and recovery of kidney function at 1 month. Results: A total of 15 647 patients were identified with biochemical AKI stage 3. Case note reviews were available for 7726 patients. In 80%, biochemical AKI stage 3 was confirmed clinically. Among this group, median age was 75 years, median length of stay was 12 days and the overall mortality within 1 month was 38%. Significant factors in a multivariable model predicting survival included age and some causes of AKI. Dipstick urinalysis, medication review, discussion with a nephrologist and acceptance for transfer to a renal unit were also associated with higher survival, but not early review by a senior doctor, acceptance for transfer to critical care or requirement for renal replacement therapy. Eighteen percent of people did not have their kidney function checked 1 month after the episode had resolved. Discussion/Conclusions: This large study of in-hospital AKI supports the efficacy of biochemical detection of AKI in common usage. AKI mortality remains substantial, length of stay comparable with single-centre studies, and much of the variation is poorly explained (model Cox and Snell R 2 ¼ 0.131) from current predictors.
Background
Acute kidney injury (AKI) is the rapid decrease in kidney function over days or weeks. It is common amongst acute admissions to hospital with 5-20% of acutely admitted patients experiencing an episode of AKI during the course of their illness. 1, 2 It is commonly associated with episodes of acute inter-current illness and is more likely in those with chronic kidney disease (CKD) or diabetes. 3 Although seldom the sole cause of a patients' death, AKI is associated with significant mortality. 4 Consensus has been reached on a classification for severity of AKI 5 that has been useful in demonstrating that both mortality and length of stay increase progressively up to the most severe stage 3 AKI. 2 Despite this care of AKI in the UK has been assessed as sub-optimal, with the review of care in national selection of patients coded as dying with AKI during 2009 concluding that AKI could have been avoided in 14%, and that care was adequate in only 50% of cases. 6 
Aim
The study reported here was designed to explore the outcomes of patients with the most severe stage of AKI (AKI3) across a sample of acute hospital trusts in UK. We examined the impact of a range of national and international recommendations for good AKI care such as timely senior medical review, medication review and discussion with a nephrologist on patient outcome.
Design
Cohort study of patients identified with AKI3 during 5-month period 1 August 2012 to 31 December 2012.
Methods
All 168 acute NHS Trusts in UK were invited (by letter to all medical directors) to take part in an audit comparing AKI incidence and assessing care quality and outcome for quality improvement purposes. Data were received from 46 organizations. This study is the further analysis of the non-identifiable information collected. Published guidance and correspondence with the UK Health Research Authority confirmed that ethical approval was not required for this study. Each trust used an automated system to identify adult patients (aged 18 years) with suspected AKI stage 3 using the hospital pathology system each month between 1 August 2012 and 31 December 2012 (5 months). Case selection criteria were based on the Kidney Disease: Improving Global Outcomes (KDIGO) guidance 5 and required an increase in serum creatinine measured during admission 3-fold from baseline or an absolute rise in creatinine >354 mmol/l. In this study, the baseline value was defined as the closest single creatinine to the date of admission in the preceding 12 months (from an inpatient or outpatient location). Patients with no creatinine results in the preceding 12 months and with an admission creatinine >354 mmol/L were considered to have AKI in this study. Organizations already identifying patients with AKI using alternative criteria (for instance, using a different assessment of baseline, or imputing a baseline if none was available) were allowed to submit data using their existing algorithm to allow comparison in positive predictive value (PPV, the probability that an individual identified by the algorithm had AKI3 on clinical review) between methods. Sites excluded patients with advanced CKD including those with end-stage renal disease (ESRD) where possible using a locally determined methodology. Coded, non-identifiable data on patients identified with AKI3 by biochemical criteria were sent to the East Midlands Public Health Observatory (EMPHO) who returned to trusts each month a randomized list of 40 cases to review the notes. Notes were reviewed against a standard pro-forma based on national and international care guidelines and standards, 6-8 supported by specific coding guidance and included clinical validation of the presence of AKI stage 3. The notes review was conducted by a senior hospital doctor (general physician or nephrologist) supported by an administrator. Patient and kidney outcome at 1 month was collected, and data were returned to EMPHO for analysis. All the analysis of patient care and outcome are based on the subset of patients with a case note review. and 168 acute NHS trusts 11 (31% with main renal unit) at the time of the study. In total, 15 647 patient biochemical records were submitted by trusts that fulfilled the biochemical criteria for AKI3, and 8133 episodes of AKI were randomly selected for case note review. Case-note review data were available from 6041 patients who fulfilled the biochemical criteria for AKI3, had a care review that confirmed AKI was clinically present, and had the principle outcome (survival at 1 month) recorded. Four hundred and seven patients were excluded because the case-note review was not completed (return rate 95%). A total of 1563 patients were excluded as after note review, they were not felt clinically to have had AKI (647 cases of CKD, 575 cases of ESRD and 334 for "other reasons"). Eighty-nine patients were excluded from the analysis as the primary outcome measure (alive at 1 month) was missing.
Statistical analysis
Characteristics of the 46 trusts who supplied data are shown in Table 1 . Trusts returned case-note reviews between 57 and 210 patients, confirming between 31 and 210 cases of AKI. The proportion of patients detected by the biochemical algorithm who were confirmed to have AKI varied considerably between organizations, with only 16% PPV at worst, and 100% at best. Centres with the highest PPV were generally centres with wellestablished local detection algorithms. Overall, the PPV was 79.7%. The clinical validated incidence of AKI3 is expressed per thousand un-planned hospital admissions as it is recognized that the majority of cases of AKI occur in patients admitted acutely. The results are very similar if presented by total hospital admissions (data not shown). Overall, the crude rate of AKI3 detected biochemically and confirmed clinically was 12.7 per 1000 un-planned hospital admissions (median, 12.4; interquartile range, 10.0115.3).
Demographics
The median age of the group with clinically confirmed AKI3 was 75 years (range, 16-99 years), and 3404 were men (56.0%). The majority of patients were recorded as White (5, 126, 93 .6%), with 170 South Asian, 111 Black, 70 others and 653 (10.7%) not known.
Care processes
The proportion of patients who received each of the care processes is summarized in Table 2 . Early Warning Score (EWS) was implemented to some degree in all but in one trust that reported no use of the EWS in any of their patients reviewed. A percentage of 35.7 patients were discussed with a renal unit, and 8.7% accepted for transfer, whereas 20.1% of patients transferred to intensive treatment unit (ITU). Eighty-three people transferred to both settings. Overall, 12.9% required RRT, but although 17.4% of those aged 18-30 years required RRT, only 9.0% of those aged 75 years and over required RRT (v 2 ¼7.007, P ¼ 0.008).
There was a positive association between dipstick testing and both senior review and discussion with a nephrologist. A percentage of 67.2 patients who had been discussed with a nephrologist had a urine dipstick test, whereas this occurred in only 48.8% of those who were not discussed (v 2 ¼ 179.649, P < 0.001). With senior review 57.0% had a urine dipstick compared with 45.2% of those who did not have a senior review (v 2 ¼ 39.110, P < 0.001).
Outcomes
Median length of stay for the whole group with AKI was 12 days. Those who were alive at 1 month had a longer median length of stay (14 days) than those who had died (8 days) (Wilcoxon rank sum P < 0.001). The variation in outcome by trust is shown in Table 3 . A total of 3729 people were alive at 1 month to have an assessment of kidney function. In 19.4%, kidney function was not 
Multivariable model
Six factors (increasing age, dipstick urinalysis, medication review, discussion with a nephrologist, acceptance for transfer to a renal unit and cause of AKI) significantly influenced the probability of being alive 1 month after AKI3 alert, and these along with their effects are summarized in Table 4 .
Discussion
These data represent the largest comparison of the implementation of nationally mandated care processes (recommended by National Institute for Health and Care Excellence and others), and outcomes in severe AKI in the UK.
Variation in PPV of detection algorithm
Across all the centres, the PPV was 79.7%, meaning that one in five patients identified biochemically as having AKI stage 3 did not have this on clinical review. Some centres have a much higher PPV close to 100%, whereas other centres clearly struggled to consistently identify individuals with AKI3. The algorithm used by the majority of centres in this study was modified from an earlier UK study 12 and was chosen pragmatically as one simple enough to be adopted by all centres. Since this study, NHS England has mandated a standard algorithm to detect biochemical AKI that has been positively assessed against historical data. 13 Like the algorithm in this study the NHS England algorithm considers a creatinine value up to 365 days before the current value, but unlike this study, it excludes patients with no baseline value, and for patients with values >7 days earlier uses a median of the previous values, rather than of a single result. Many of the centres with high PPV in this study had been developing detection methods over many years, and in particular had successfully developed methods for using a lowest or an average (mean or median) creatinine value over a different time period (3, 6 and 12 months) and in particular methods to reliably exclude patients with CKD and those on dialysis. Variation in incidence of AKI
The trust median incidence of AKI3 was 12.4 per 1000 unplanned hospital admissions and is very similar to other singlecentre series. 2 The interquartile range is also narrow with an 1.8-fold variation in incidence within that group (10.0-15.3 per 1000 un-planned admissions). Organizations outside that range had considerable variation in incidence which may relate to differences in the detection method, or case-mix (although further studies would be required to prove this). Common population factors known to affect disease incidence and outcome such as deprivation or ethnic group have not been well studied in AKI. It seems likely that at least some of the differences represent different populations served, but it would be crucial to understand this variation before any attempt is made by policy makers to set an achievable target rate of AKI in all populations.
Care process measures
For several conditions, it is established that the delivery of key care steps is associated with better outcome. Examples include outpatient diabetes care, 14 and assessment of the acutely unwell adult. 8 The evidence for key treatment processes for patients with AKI is less good although there is some evidence that AKI alerts can drive earlier interventions and that these in turn may improve outcome. 15 Rates of review by a senior clinician within 12 hours of admission to hospital, and then adoption of a physiological measurement warning system to prompt senior re-review were high (86.0 and 81.3% of cases, respectively), and only one organization had no warning system in place. These were both key recommendations of the previous study of care provided to patients in UK identified with AKI in whom care was often judged to have been suboptimal 6 .
Renal advice, renal and ITU transfer A percentage of 35.7 patients were discussed with a nephrologist, and 8.6% were accepted for transfer to a renal unit, whereas 20.1% of patients were accepted for transfer to ITU. This includes 89 people who were accepted for transfer to both settings. Discussion with a nephrologist was associated with a 1.5-fold increase in 1-month survival, and acceptance for transfer to a renal unit with a 2.4-fold increase, in a model that included likely confounding factors such as patient age, and the final cause of AKI. Acceptance for transfer to ITU appeared to have no effect. Not all patients who transfer to either a renal unit or an ITU received RRT (42.5% and 39.1% receiving RRT, respectively), and significantly there was no difference in the likelihood of sending a patient to an ICU, or in committing a patient to RRT, in centres with and without renal units. Most but not all ITU settings would have been able to provide RRT at the time of this study, but the ability to access either ITU and renal unit beds will have varied significantly between sites and is likely to have influenced decision making.
In the multi-variable model, RRT was not significantly associated with patient outcome. It is not possible to tell from this study whether this means that RRT was being offered to appropriate individuals or whether this is a self-fulfilling strategy where the full potential of wider use of RRT to all patients could be shown to alter outcome.
Overall outcome
Overall, 38.3% of the patients clinically validated to have AKI3 died within 1 month of developing AKI3, and the median length of hospital stay for all patients with AKI3 was 12 days. Both are similar to that reported in other studies. 2 Crude -month mortality varied considerably between trusts from 17.6% to 75.0%. These data are not adjusted for age or case-mix, which might explain some of the variation, as might differences in access to case-notes in those who were still alive or died in some organizations. It is also recognized that trusts organizational characteristics might affect outcomes, with the presence of a renal units, or even more so a renal transplant unit being associated with better hospital outcome previously. 16 Although not included in our final model that was limited to individual and not ecological factors, the presence of a renal centre in multivariable analysis was not associated with a difference in 1-month mortality in this study. Recovery of kidney function was the norm, with only 1.7% of the original cohort (3.3% those alive at 1 month) continuing to require RRT at 1 month. However, almost one in three of those alive (30.9%) did not recover to their baseline kidney function with a likely long-term effect on their health 17, 18 and also cost to the health service.
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Factors predicting survival from AKI at 1 month Each increase in age by 1 year was associated with a 4% increased risk of being dead at 1 month. Sepsis and cause "other" were both associated with a worse outcome than hypovolaemia alone, whereas nephrotoxic drugs or urinary tract obstruction as the causes conferred a better outcome. "Other" is likely to represent patients with multiple causes. Acceptance for transfer to a renal unit is associated with a 2.4-fold greater odds of survival. It cannot exclude a clinically likely selection bias in transfer to renal units, and it is not explained simply by access to RRT as this did not itself have any association with outcome. Neither ITU transfer (also subject to selection bias) nor senior review within 12 hours appears to provide benefit. The latter is disappointing as intuitively this would appear to be a good candidate for improving outcomes. It is not entirely clear about the explanation behind the observation that having a urine dipstick tested is associated with a better survival. A possible explanation is found in the association between dipstick testing and both senior review and discussion with a nephrologist. It could be speculated that the urine dipstick test reflects attention to detail by the attending physician supported by discussion with a nephrologist.
Overall, the model explains only 13.1% (Cox and Snell R 2 ¼0.131) of the variation in patient survival, and majority of the effect is explained by patient age. It has previously been shown that mortality in patients who developed AKI after cardiac surgery is affected by pre-existing conditions (congestive heart failure, pre-operative creatinine level) and illness severity (requiring ventilation or balloon pump). 20 It is a limitation of this study that we cannot account for such factors. Therefore, it must be acknowledged that the majority of the variation is likely to be in unmeasured differences in patient characteristics, disease process or care.
